Cryoprobe Biopsy and Chronic Rejection in Lung Transplant Recipients
NCT: NCT06824402 · RECRUITING
Brief Summary
The goal of this clinical trial is to evaluate which biopsy collection method helps to better diagnose rejection and relevant pathologic findings in lung transplant recipients. The main questions it aims to answer are: Does the 1.1 mm cryoprobe or the biopsy forceps provide better quality samples of lung tissue for detecting rejection in transplant recipients? How much tissue is adequate for lung transplant 1.1 mm cryobiopsy samples as compared to biopsy forceps? Which samples received by the pathologist did they find they were most confident to exclude rejection, based on their satisfaction with the samples? Which collection method has the least amount of procedural time? Researchers will compare lung tissue samples obtained using a 1.1mm cryoprobe and a biopsy forceps during the lung transplant. Participants will: Be randomly assigned to receive either the cryoprobe or biopsy forceps collection method at the time of biopsy. Assessed for any adverse events following the biopsy for up to 30 days after transplant.
Frequently Asked Questions
What is Cryoprobe Biopsy and Chronic Rejection in Lung Transplant Recipients?
Cryoprobe Biopsy and Chronic Rejection in Lung Transplant Recipients is a clinical trial registered under NCT06824402. Current status: RECRUITING.
What is the status of NCT06824402?
The current status of NCT06824402 (Cryoprobe Biopsy and Chronic Rejection in Lung Transplant Recipients) is: RECRUITING.
When did Cryoprobe Biopsy and Chronic Rejection in Lung Transplant Recipients start?
Cryoprobe Biopsy and Chronic Rejection in Lung Transplant Recipients started on 2025-02-17.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.